Identifying molecular targets that cause nerve damage from cancer drugs.
High-throughput identification of molecular targets responsible for drug-induced peripheral neuropathies.
This study is looking into why some cancer treatments can cause painful nerve damage, using zebrafish to find out what causes these side effects, and then checking the results in mice to help develop better ways to protect patients from this discomfort during their treatment.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10371819 on NIH RePORTER |
What this research studies
This research investigates the causes of drug-induced peripheral neuropathies (DIPNs), which are painful nerve damages often resulting from cancer treatments. By using a high-content screening method in zebrafish, the study aims to identify specific molecular targets responsible for these side effects. The researchers will also validate their findings in mouse models to understand how certain drugs affect nerve cells. This approach could lead to better strategies for preventing or mitigating nerve damage in patients undergoing cancer therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are experiencing or are at risk of developing drug-induced peripheral neuropathies.
Not a fit: Patients who are not undergoing cancer treatment or do not experience peripheral neuropathies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments with fewer side effects related to nerve damage.
How similar studies have performed: Previous research has shown success in identifying neurotoxic effects of drugs using similar high-throughput screening methods, indicating a promising approach.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Nechiporuk, Alex — Oregon Health & Science University
- Study coordinator: Nechiporuk, Alex
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.